Platelets . Alterations in platelets during SARS-CoV-2 infection

[tetano]

Platelets


. 2021 Aug 13;1-9.
doi: 10.1080/09537104.2021.1962519. Online ahead of print.
Alterations in platelets during SARS-CoV-2 infection


Marta Brambilla ¹ , Paola Canzano ¹ , Alessia Becchetti ¹ , Elena Tremoli ² , Marina Camera ^{1 3}



Affiliations

• PMID: 34384321
• DOI: 10.1080/09537104.2021.1962519

Abstract

Coronavirus disease 2019 (COVID-19) is a pandemic syndrome caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. SARS-CoV-2 infection induces a process of inflammation and thrombosis supported by an altered platelet activation state. This platelet activation is peculiar being characterized by the formation of platelet-leukocytes rather than platelet-platelet aggregates and by an increased procoagulant potential supported by elevated levels of TF positive platelets and microvesicles.Therapeutic strategies targeting, beyond systemic inflammation (i.e. with tocilizumab, an anti interleukin-6 receptor), this state of platelet activation might therefore be beneficial. Among the antithrombotic drugs proposed as candidates to treat patients with SARS-CoV-2 infection, antiplatelet drugs, such as aspirin are showing promising results.

Keywords: Antiplatelet drugs; COVID-19; coagulation; platelets; thrombosis.